Mapping of the outcome measures in rheumatology core set for antineutrophil cytoplasmic antibody-associated vasculitis to the international classification of function, disability and health

Arthritis Care and Research

Volumn 67, Issue 2, 2015, Pages 255-263

  Milman, Nataliya ^a   Boonen, Annelies ^b   Merkel, Peter A ^c   Tugwell, Peter ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANCA ASSOCIATED VASCULITIS; ARTICLE; DAILY LIFE ACTIVITY; DISEASE ACTIVITY; FUNCTIONAL ASSESSMENT; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; OUTCOME ASSESSMENT; RHEUMATOLOGY; SHORT FORM 36; CLASSIFICATION;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RHEUMATOLOGY;

EID: 84922070184     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22414     Document Type: Article

References (27)

1. World Health Organization. ICF-international classification of functioning, disability and health. Geneva: World Health Organization Library; 2001.
2. Kostanjsek N. Use of the international classification of functioning, disability and health (ICF) as a conceptual framework and common language for disability statistics and health information systems. BMC Public Health 2011;Suppl 4:S3.
3. Cieza A, Ewert T, Ustun TB, Chatterji S, Kostanjsek N, Stucki G. Development of ICF core sets for patients with chronic conditions. J Rehabil Med 2004;Suppl:9-11.
4. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38-43.
5. Boonen A, Stucki G, Maksymowych W, Rat AC, Escorpizo R, Boers M, and the OMERACT-ICF Reference Group. Integrating the ICF into the OMERACT process: opportunities and challenges. J Rheumatol 2009;36:2057-60.
6. Merkel PA, Aydin SZ, Boers M, Direskeneli H, Herlyn K, Seo P, et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol 2011;38:1480-6.
7. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
8. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-32.
9. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al, for the International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001;44:912-20.
10. Luqmani RA, Exley AR, Kitas GD, Bacon PA. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997;11:423-46.
11. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
12. McHorney CA, Ware JE Jr, Rogers W, Raczek AE, Lu JF. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts: results from the Medical Outcomes Study. Med Care 1992;30 Suppl: MS253-65.
13. Merkel PA, Cuthbertson DD, Hellmich B, Hoffman GS, Jayne DR, Kallenberg CG, et al. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis 2009;68:103-6.
14. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I: Conceptual framework and item selection. Med Care 1992;30:473-83.
15. Cieza A, Brockow T, Ewert T, Amman E, Kollerits B, Chatterji S, et al. Linking health-status measurements to the international classification of functioning, disability and health. J Rehabil Med 2002;34:205-10.
16. Cieza A, Geyh S, Chatterji S, Kostanjsek N, Ustun B, Stucki G. ICF linking rules: an update based on lessons learned. J Rehabil Med 2005;37:212-8.
17. Rat AC, Guillemin F, Pouchot J. Mapping the osteoarthritis knee and hip quality of life (OAKHQOL) instrument to the international classification of functioning, disability and health and comparison to five health status instruments used in osteoarthritis. Rheumatology (Oxford) 2008;47:1719-25.
18. Sigl T, Cieza A, van der Heijde D, Stucki G. ICF based comparison of disease specific instruments measuring physical functional ability in ankylosing spondylitis. Ann Rheum Dis 2005;64:1576-81.
19. Cieza A, Stucki G. Content comparison of health-related quality of life (HRQOL) instruments based on the international classification of functioning, disability and health (ICF). Qual Life Res 2005;14:1225-37.
20. Simon LS, Strand V, Bingham CO III, Singh JA. OMERACT 11: International Consensus Conference on Outcome Measures in Rheumatology. J Rheumatol 2014;41:145-9.
21. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745-53.
22. Merkel PA, Aydin SZ, Boers M, Cornell C, Direskeneli H, Gebhart D, et al. Current status of outcome measure development in vasculitis. J Rheumatol 2014;41:593-8.
23. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
24. Escorpizo R, Boers M, Stucki G, Boonen A. Examining the similarities and differences of OMERACT core sets using the ICF: first step towards an improved domain specification and development of an item pool to measure functioning and health. J Rheumatol 2011;38:1739-44.
25. Schwarzkopf SR, Ewert T, Dreinhofer KE, Cieza A, Stucki G. Towards an ICF Core set for chronic musculoskeletal conditions: commonalities across ICF core sets for osteoarthritis, rheumatoid arthritis, osteoporosis, low back pain and chronic widespread pain. Clin Rheumatol 2008;27:1355-61.
26. Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al, for the WGET Research Group. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78.
27. Gossec L, Kirwan J, de Wit M. Patient perspective in outcome measures developed by OMERACT. Indian J Rheumatol 2013; Suppl 1:S17-22.